SPRY3 and acute myeloid leukemia: In other work, GSK-3α and downstream SPRY3 were found to be markedly downregulated in quizartinib-resistant FLT3-ITD–expressing AML cells, associated with restored RAS/MAPK or Wnt signaling, and knockout of GSK-3α and GSK-3β or SPRY3 conferred resistance to quizartinib (53).